A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

• Status: Terminated
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the pharmacokinetics of MK-0941 in participants with varying degrees of renal insufficiency.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Male or nonpregnant female age 18 to 75 years

• Female of childbearing potential on appropriate method of contraception

• Body mass index (BMI) less than or equal to 40 kg/m2

• Participant is in good health

• Participant diagnosed with Type 2 Diabetes

• Participant agrees to follow smoking restrictions

• Willing to follow the study diet restrictions

Exclusion Criteria:

• Mental or legal incapacitation

• Participant has had kidney removed

• History of Type 1 diabetes

• History of stroke, chronic seizures or major neurological disorder

• History of neoplastic disease

• Nursing mother

• Consumes greater than 4 glasses of alcoholic beverages per day

• Consumes greater than 6 servings of caffeinated beverages per day

• Participant has had surgery or donated 1 unit of blood within 1 month of screening

• Participant has history of recent eye infection within 2 weeks of study drug administration

• Clinically diagnosed with glaucoma or blindness

• Has trauma to one or both eyes